DAPAGLIFLOZIN

Generic: DAPAGLIFLOZIN

Sandoz IncManufacturer
ORALRoute
DAPAGLIFLOZINActive Substance
2026-04-06Original Approval

DAPAGLIFLOZIN is FDA application ANDA211312, sponsored by SANDOZ. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Top Reported Reactions

1
DEATH
4,787 reports
2
ACUTE KIDNEY INJURY
1,730 reports
3
OFF LABEL USE
1,442 reports
4
DYSPNOEA
1,422 reports
5
DIARRHOEA
1,369 reports
6
NAUSEA
1,367 reports
7
FATIGUE
1,346 reports
8
DIZZINESS
1,281 reports
9
VOMITING
1,220 reports
10
DIABETIC KETOACIDOSIS
1,091 reports